MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 326803 | Name: Pirodavir
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Pirodavir, also known as R 77975, is a capsid-binding antipicornavirus agent with potent in vitro activity against both group A and group B rhinovirus serotypes. Pirodavir was one of the most promising capsid-binding compounds to show efficacy in human clinical trials for chemoprophylaxis of the common cold.

Chemical Structure

Pirodavir
Pirodavir
CAS#124436-59-5

Theoretical Analysis

MedKoo Cat#: 326803

Name: Pirodavir

CAS#: 124436-59-5

Chemical Formula: C21H27N3O3

Exact Mass: 369.2052

Molecular Weight: 369.47

Elemental Analysis: C, 68.27; H, 7.37; N, 11.37; O, 12.99

Price and Availability

Size Price Availability Quantity
50mg USD 450.00 2 Weeks
100mg USD 850.00 2 Weeks
200mg USD 1,250.00 2 Weeks
500mg USD 1,650.00 2 Weeks
1g USD 2,650.00 2 Weeks
2g USD 4,750.00 2 Weeks
5g USD 6,850.00 2 Weeks
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
R 77975; R-77975; R77975; R77,975; R 77,975; R-77,975; Pirodavir.
IUPAC/Chemical Name
Ethyl p-(2-(1-(6-methyl-3-pyridazinyl)-4-piperidyl)ethoxy)benzoate
InChi Key
KCHIOGFOPPOUJC-UHFFFAOYSA-N
InChi Code
InChI=1S/C21H27N3O3/c1-3-26-21(25)18-5-7-19(8-6-18)27-15-12-17-10-13-24(14-11-17)20-9-4-16(2)22-23-20/h4-9,17H,3,10-15H2,1-2H3
SMILES Code
O=C(OCC)C1=CC=C(OCCC2CCN(C3=NN=C(C)C=C3)CC2)C=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Pirodavir is a potent, broad-spectrum picornavirus inhibitor.
In vitro activity:
Pirodavir (R 77975) is the prototype of a novel class of broad-spectrum antipicornavirus compounds. Although its predecessor, R 61837, a substituted phenyl-pyridazinamine, was effective in inhibiting 80% of 100 serotypes tested (EC80) at concentrations above 32 micrograms/ml, pirodavir inhibits the same percentage of viruses at 0.064 micrograms/ml. Whereas R 61837 was active almost exclusively against rhinovirus serotypes of antiviral group B, pirodavir is broad spectrum in that it is highly active against both group A and group B rhinovirus serotypes. Pirodavir is also effective in inhibiting 16 enteroviruses, with an EC80 of 1.3 micrograms/ml. Pirodavir acts at an early stage of the viral replication cycle (up to 40 min after infection) and reduces the yield of selected rhinoviruses 1,000- to 100,000-fold in a single round of replication. Reference: Antimicrob Agents Chemother. 1992 Jan;36(1):100-7. https://pubmed.ncbi.nlm.nih.gov/1317142/
In vivo activity:
TBD
Solvent mg/mL mM comments
Solubility
DMF 30.0 81.20
DMF:PBS (pH 7.2) (1:3)] 0.3 0.68
DMSO 10.0 27.07
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 369.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Smee DF, Evans WJ, Nicolaou KC, Tarbet EB, Day CW. Susceptibilities of enterovirus D68, enterovirus 71, and rhinovirus 87 strains to various antiviral compounds. Antiviral Res. 2016 Jul;131:61-5. doi: 10.1016/j.antiviral.2016.04.003. Epub 2016 Apr 7. PMID: 27063860; PMCID: PMC5100981. 2. Andries K, Dewindt B, Snoeks J, Willebrords R, van Eemeren K, Stokbroekx R, Janssen PA. In vitro activity of pirodavir (R 77975), a substituted phenoxy-pyridazinamine with broad-spectrum antipicornaviral activity. Antimicrob Agents Chemother. 1992 Jan;36(1):100-7. doi: 10.1128/AAC.36.1.100. PMID: 1317142; PMCID: PMC189235.
In vitro protocol:
1. Smee DF, Evans WJ, Nicolaou KC, Tarbet EB, Day CW. Susceptibilities of enterovirus D68, enterovirus 71, and rhinovirus 87 strains to various antiviral compounds. Antiviral Res. 2016 Jul;131:61-5. doi: 10.1016/j.antiviral.2016.04.003. Epub 2016 Apr 7. PMID: 27063860; PMCID: PMC5100981. 2. Andries K, Dewindt B, Snoeks J, Willebrords R, van Eemeren K, Stokbroekx R, Janssen PA. In vitro activity of pirodavir (R 77975), a substituted phenoxy-pyridazinamine with broad-spectrum antipicornaviral activity. Antimicrob Agents Chemother. 1992 Jan;36(1):100-7. doi: 10.1128/AAC.36.1.100. PMID: 1317142; PMCID: PMC189235.
In vivo protocol:
TBD
1: Tang Q, Xu Z, Zhang F, Cai Y, Chen Y, Lu B, Zhou HB, Lan K, Wu S. Identification of a novel binding inhibitor that blocks the interaction between hSCARB2 and VP1 of enterovirus 71. Cell Insight. 2022 Feb 12;1(2):100016. doi: 10.1016/j.cellin.2022.100016. PMID: 37193133; PMCID: PMC10120312. 2: Lanko K, Shi C, Patil S, Delang L, Matthijnssens J, Mirabelli C, Neyts J. Assessing In Vitro Resistance Development in Enterovirus A71 in the Context of Combination Antiviral Treatment. ACS Infect Dis. 2021 Oct 8;7(10):2801-2806. doi: 10.1021/acsinfecdis.0c00872. Epub 2021 Sep 16. PMID: 34529400. 3: Roy Chattopadhyay N, Chatterjee K, Banerjee A, Choudhuri T. Combinatorial therapeutic trial plans for COVID-19 treatment armed up with antiviral, antiparasitic, cell-entry inhibitor, and immune-boosters. Virusdisease. 2020 Dec;31(4):479-489. doi: 10.1007/s13337-020-00631-w. Epub 2020 Nov 11. PMID: 33200085; PMCID: PMC7657379. 4: Wang Y, Wang H, Jiang X, Jiang Z, Guo T, Ji X, Li Y, Li Y, Li Z. Synthesis and Broad Antiviral Activity of Novel 2-aryl-isoindolin-1-ones towards Diverse Enterovirus A71 Clinical Isolates. Molecules. 2019 Mar 11;24(5):985. doi: 10.3390/molecules24050985. PMID: 30862068; PMCID: PMC6429200. 5: Ke S, Li N, Ke T, Shi L, Zhang Z, Fang W, Zhang YN, Wang K, Zhou R, Wan Z, Yang Z, Zhang G, Wei Y. Synthesis and evaluation of steroidal thiazoline conjugates as potential antiviral agents. Future Med Chem. 2018 Nov;10(22):2589-2605. doi: 10.4155/fmc-2018-0075. Epub 2018 Nov 30. PMID: 30499701. 6: Wang HQ, Hu J, Yan HY, Wu S, Li YH. Corydaline inhibits enterovirus 71 replication by regulating COX-2 expression. J Asian Nat Prod Res. 2017 Nov;19(11):1124-1133. doi: 10.1080/10286020.2017.1386658. Epub 2017 Oct 15. PMID: 29034730. 7: Smee DF, Evans WJ, Nicolaou KC, Tarbet EB, Day CW. Susceptibilities of enterovirus D68, enterovirus 71, and rhinovirus 87 strains to various antiviral compounds. Antiviral Res. 2016 Jul;131:61-5. doi: 10.1016/j.antiviral.2016.04.003. Epub 2016 Apr 7. PMID: 27063860; PMCID: PMC5100981. 8: Jiang Z, Wang H, Li Y, Peng Z, Li Y, Li Z. Synthesis and antiviral activity of a series of novel N-phenylbenzamide and N-phenylacetophenone compounds as anti-HCV and anti-EV71 agents. Acta Pharm Sin B. 2015 May;5(3):201-9. doi: 10.1016/j.apsb.2015.03.013. Epub 2015 Apr 8. PMID: 26579447; PMCID: PMC4629265. 9: Sun L, Meijer A, Froeyen M, Zhang L, Thibaut HJ, Baggen J, George S, Vernachio J, van Kuppeveld FJ, Leyssen P, Hilgenfeld R, Neyts J, Delang L. Antiviral Activity of Broad-Spectrum and Enterovirus-Specific Inhibitors against Clinical Isolates of Enterovirus D68. Antimicrob Agents Chemother. 2015 Dec;59(12):7782-5. doi: 10.1128/AAC.01375-15. Epub 2015 Sep 14. PMID: 26369972; PMCID: PMC4649165. 10: Lacroix C, Laconi S, Angius F, Coluccia A, Silvestri R, Pompei R, Neyts J, Leyssen P. In vitro characterisation of a pleconaril/pirodavir-like compound with potent activity against rhinoviruses. Virol J. 2015 Jul 14;12:106. doi: 10.1186/s12985-015-0330-4. PMID: 26169596; PMCID: PMC4501209. 11: Bernard A, Lacroix C, Cabiddu MG, Neyts J, Leyssen P, Pompei R. Exploration of the anti-enterovirus activity of a series of pleconaril/pirodavir-like compounds. Antivir Chem Chemother. 2015 Apr;24(2):56-61. doi: 10.1177/2040206615589035. Epub 2015 Jun 11. PMID: 26071135; PMCID: PMC5890516. 12: Schotte L, Thys B, Strauss M, Filman DJ, Rombaut B, Hogle JM. Characterization of Poliovirus Neutralization Escape Mutants of Single-Domain Antibody Fragments (VHHs). Antimicrob Agents Chemother. 2015 Aug;59(8):4695-706. doi: 10.1128/AAC.00878-15. Epub 2015 May 26. PMID: 26014941; PMCID: PMC4505203. 13: Tijsma A, Franco D, Tucker S, Hilgenfeld R, Froeyen M, Leyssen P, Neyts J. The capsid binder Vapendavir and the novel protease inhibitor SG85 inhibit enterovirus 71 replication. Antimicrob Agents Chemother. 2014 Nov;58(11):6990-2. doi: 10.1128/AAC.03328-14. Epub 2014 Sep 8. PMID: 25199773; PMCID: PMC4249361. 14: Tijsma A, Thibaut HJ, Spieser SA, De Palma A, Koukni M, Rhoden E, Oberste S, Pürstinger G, Volny-Luraghi A, Martin J, Marchand A, Chaltin P, Neyts J, Leyssen P. H1PVAT is a novel and potent early-stage inhibitor of poliovirus replication that targets VP1. Antiviral Res. 2014 Oct;110:1-9. doi: 10.1016/j.antiviral.2014.07.003. Epub 2014 Jul 17. PMID: 25043639. 15: Bernard AM, Cabiddu MG, De Montis S, Mura R, Pompei R. Synthesis of new compounds with promising antiviral properties against group A and B Human Rhinoviruses. Bioorg Med Chem. 2014 Aug 1;22(15):4061-6. doi: 10.1016/j.bmc.2014.05.066. Epub 2014 Jun 12. PMID: 24973816. 16: Mello C, Aguayo E, Rodriguez M, Lee G, Jordan R, Cihlar T, Birkus G. Multiple classes of antiviral agents exhibit in vitro activity against human rhinovirus type C. Antimicrob Agents Chemother. 2014;58(3):1546-55. doi: 10.1128/AAC.01746-13. Epub 2013 Dec 23. PMID: 24366736; PMCID: PMC3957863. 17: Ji XY, Wang HQ, Hao LH, He WY, Gao RM, Li YP, Li YH, Jiang JD, Li ZR. Synthesis and antiviral activity of N-phenylbenzamide derivatives, a novel class of enterovirus 71 inhibitors. Molecules. 2013 Mar 21;18(3):3630-40. doi: 10.3390/molecules18033630. PMID: 23519203; PMCID: PMC6270001. 18: Laconi S, Madeddu MA, Pompei R. Study of the biological activity of novel synthetic compounds with antiviral properties against human rhinoviruses. Molecules. 2011 Apr 26;16(5):3479-87. doi: 10.3390/molecules16053479. PMID: 21522081; PMCID: PMC6263271. 19: Yan H, Liu Y, Lu XQ, Gong ZH. [Establishment of isolated rabbit airway smooth muscles responsiveness model for the pharmacodynamic study of anti- rhinoviruses drugs]. Yao Xue Xue Bao. 2010 Apr;45(4):436-41. Chinese. PMID: 21355207. 20: Fan SY, Zheng ZB, Mi CL, Zhou XB, Yan H, Gong ZH, Li S. Synthesis and evaluation of novel chloropyridazine derivatives as potent human rhinovirus (HRV) capsid-binding inhibitors. Bioorg Med Chem. 2009 Jan 15;17(2):621-4. doi: 10.1016/j.bmc.2008.11.061. Epub 2008 Dec 3. PMID: 19091578.